Clinical trial
A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial To Evaluate the Efficacy and Safety of Telmisartan Compared With Losartan in Patients With Diabetic Nephropathy and Hypertension
NCT06431477 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Open-label, Active Comparator-controlled, Phase 4 Clinical Trial To Evaluate the Efficacy and Safety of Telmisartan Compared With Losartan in Patients With Diabetic Nephropathy and Hypertension
- Lead sponsor
- Chong Kun Dang Pharmaceutical
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- April 19, 2023
- Completion date
- October 31, 2025
- Enrollment
- 98 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.